SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (633)1/24/2001 6:29:08 PM
From: software salesperson  Respond to of 3044
 
wilder,

yes. the answer was near the end of the call. so if you just wanted to listen to that part, you could move the real player arrow there.

i don't remember the question to be about calp per se. i believe that the question concerned their integrated platform and its components. levin spoke most highly about how calp's microfluidics helped them. but i'm not technical enough to remember , or understand, the details.

sales



To: keokalani'nui who wrote (633)1/24/2001 10:37:55 PM
From: rkrw  Read Replies (1) | Respond to of 3044
 
The CALP comments were not prompted by a question.

Levin was highlighting prominent mlnm technology alliances. Medarex, abgenix and morphosys for antibodies. Aventis and admet. The biocore alliance and broad Calp alliance for microfluidics.

I've seen Levin present a couple of times. He gushes about calp technology. mlnm is integrating calp microfluidic technology across the company.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News